KIZZIE HOUSTON: Open Payments
NPI 1225620149 · LITTLE ROCK, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,228 in 39 payments from 14 companies in 2025. Trend: 2023 $937 · 2024 $893 · 2025 $1,228
Food & beverage: $1,228
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $251 |
| Vanda Pharmaceuticals Inc. | 7 | $198 |
| Eisai Inc. | 1 | $123 |
| Axsome Therapeutics, Inc. | 1 | $117 |
| Neurelis, Inc. | 1 | $115 |
| Neurocrine BioSciences, Inc. | 4 | $83 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $70 |
| Alkermes, Inc. | 4 | $68 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| Teva Pharmaceuticals USA, Inc. | 2 | $41 |
Products named: VRAYLAR, FANAPT, Leqembi, Auvelity, VALTOCO, INGREZZA, CAPLYTA, REXULTI.
Industry payments across AR — which companies pay providers there.
